JP7219211B2 - ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法 - Google Patents

ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法 Download PDF

Info

Publication number
JP7219211B2
JP7219211B2 JP2019511910A JP2019511910A JP7219211B2 JP 7219211 B2 JP7219211 B2 JP 7219211B2 JP 2019511910 A JP2019511910 A JP 2019511910A JP 2019511910 A JP2019511910 A JP 2019511910A JP 7219211 B2 JP7219211 B2 JP 7219211B2
Authority
JP
Japan
Prior art keywords
cells
cell
platelet
blood
rich fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530439A5 (https=
JP2019530439A (ja
Inventor
ヨン ジャオ
Original Assignee
ハッケンサック ユニヴァーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハッケンサック ユニヴァーシティ メディカル センター filed Critical ハッケンサック ユニヴァーシティ メディカル センター
Publication of JP2019530439A publication Critical patent/JP2019530439A/ja
Publication of JP2019530439A5 publication Critical patent/JP2019530439A5/ja
Application granted granted Critical
Publication of JP7219211B2 publication Critical patent/JP7219211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
JP2019511910A 2016-08-29 2017-08-28 ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法 Active JP7219211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380913P 2016-08-29 2016-08-29
US62/380,913 2016-08-29
PCT/US2017/048945 WO2018044809A1 (en) 2016-08-29 2017-08-28 Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans

Publications (3)

Publication Number Publication Date
JP2019530439A JP2019530439A (ja) 2019-10-24
JP2019530439A5 JP2019530439A5 (https=) 2020-09-24
JP7219211B2 true JP7219211B2 (ja) 2023-02-07

Family

ID=61309448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511910A Active JP7219211B2 (ja) 2016-08-29 2017-08-28 ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法

Country Status (8)

Country Link
US (1) US11066648B2 (https=)
EP (1) EP3503909A4 (https=)
JP (1) JP7219211B2 (https=)
KR (1) KR20190039822A (https=)
CN (1) CN109843317A (https=)
AU (2) AU2017321314A1 (https=)
CA (1) CA3033539A1 (https=)
WO (1) WO2018044809A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2788472T (lt) 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
US11360097B2 (en) * 2015-11-12 2022-06-14 Edward J Goetzl Platelet biomarkers and diagnostic methods for vascular diseases
JP2021509812A (ja) 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
CN108642005B (zh) * 2018-05-22 2021-07-27 广州迪澳医疗科技有限公司 一种含连接剂的淋巴细胞分离液
AU2019291955A1 (en) 2018-06-29 2021-02-18 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020142769A1 (en) * 2019-01-04 2020-07-09 Kenneth Allen Pettine Isolation and use of autogenous platelet derived exosomes
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
WO2024097131A1 (en) * 2022-11-04 2024-05-10 The Board Of Trustees Of The Leland Stanford Junior University Rebalancing the immune system through depletion of myeloid-biased hematopoietic stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525994A (ja) 2003-05-12 2006-11-16 サラ ファーバー， 非膵島組織における調節された膵ホルモンの産生を誘導する方法
JP2014520523A (ja) 2011-07-06 2014-08-25 セル セラピー リミテッド 中胚葉系列の前駆細胞

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US20050260158A1 (en) * 2003-11-07 2005-11-24 Eliezer Huberman Human stem cell materials and methods
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
WO2008048671A1 (en) * 2006-10-18 2008-04-24 University Of Illinois Embryonic-like stem cells derived from adult human peripheral blood and methods of use
WO2009072003A2 (en) * 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525994A (ja) 2003-05-12 2006-11-16 サラ ファーバー， 非膵島組織における調節された膵ホルモンの産生を誘導する方法
JP2014520523A (ja) 2011-07-06 2014-08-25 セル セラピー リミテッド 中胚葉系列の前駆細胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochem Biophys Res Commun 2007, 360: 205-211

Also Published As

Publication number Publication date
US11066648B2 (en) 2021-07-20
AU2017321314A1 (en) 2019-02-28
AU2022287675A1 (en) 2023-02-02
AU2022287675B2 (en) 2025-09-18
US20180135020A1 (en) 2018-05-17
KR20190039822A (ko) 2019-04-15
CA3033539A1 (en) 2018-03-08
EP3503909A1 (en) 2019-07-03
CN109843317A (zh) 2019-06-04
WO2018044809A1 (en) 2018-03-08
JP2019530439A (ja) 2019-10-24
EP3503909A4 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
JP7177041B2 (ja) 血小板様細胞を含有する血液の血小板に富む画分を用いて成体細胞をプログラミングするための組成物および方法
JP7219211B2 (ja) ヒトにおける血小板様細胞を含有する血液の血小板に富む画分の幹細胞性により成体細胞を再プログラミングするための組成物および方法
JP2022162093A (ja) ＣＤ８α＋β＋細胞傷害性Ｔ細胞の製造方法
JP2022545782A (ja) 多能性幹細胞から造血性前駆細胞を生産する方法
JP7222884B2 (ja) Ｔ細胞区画において自己反応性を低下させることにより免疫障害関連疾患を治療する方法
JP2022545078A (ja) ＲＡＧが不活性化されたｉＰＳＣからのＴ細胞生産
US20240124841A1 (en) Methods of producing haemogenic endothelial cells from pluripotent stem cells
EP4065684A1 (en) Thymus organoids bioengineered form human pluripotent stem cells
CA3214216A1 (en) Pluripotent stem cell-derived hematopoietic lineages
JP2022545416A (ja) Ｔ細胞の生産方法
AU2023353929A1 (en) T cell production method
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
KR20250006993A (ko) 방법
HK40009594A (en) Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
EP4660299A1 (en) Production of blood and immune cell progenitors
WO2024050534A2 (en) In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same
WO2023247722A1 (en) Method for isolating hemogenic endothelial cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230126

R150 Certificate of patent or registration of utility model

Ref document number: 7219211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250